 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes In a poster presentation on Thursday, Dec. 7th at...

Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Dis

BMF-219 is a novel investigational covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes Health Canada has cleared the initiation of...

Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Biomea Fusion (BMEA Research Report), with a price tar...

Piper Sandler Sticks to Their Buy Rating for Biomea Fusion (BMEA)

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Biomea Fusion Inc (BMEA), where a total of 12,645 contracts have traded so far...

Notable Wednesday Option Activity: BMEA, FSLR, BYND

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetesNew clinical data from all dosing cohorts (n=62...

Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024

For the last three days, A.I.dvisor has detected that BMEA's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Biomea Fusion (BMEA, $9.31) Aroon Indicator entered a Downtrend on November 15, 2023.

BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure diabetesNew clinical data providing long-term 26 weeks follow-up...

Biomea Fusion Abstract  BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease

Biomea Fusion (BMEA, $8.89) Aroon Indicator entered a Downtrend on November 14, 2023.

This is a signal that BMEA's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Biomea Fusion (BMEA, $8.89) RSI Indicator left the oversold zone on November 14, 2023

Biomea Fusion (BMEA, $8.37) Aroon Indicator entered a Downtrend on November 13, 2023.

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

Market Cap	$658.77M
Volume (M)	1.18M
52-Wk High	$43.69
52-Wk Low	$6.04

BMEA Biomea Fusion Inc

About

Feed

News

Earnings

Fundamentals